Testing effectiveness (Phase 2)Looking for participantsNCT06477653
What this trial is testing
Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
Who this might be right for
Hypereosinophilic Syndrome
National Institute of Allergy and Infectious Diseases (NIAID) 30